Forward PE Ratio: 14.08
The forward PE ratio is 14.08 as of Thursday, July 9, 2026.
Forward PE Ratio (14.08) = Close Price ($102.81) / Consensus Forward EPS ($7.42)
CVS Forward PE Ratio Metrics
FORWARD PE RATIO
14.08
CVS Competitors' Forward PE Ratio
CVS Health Corp.
Market Cap
$131.18B
Forward PE Ratio
14.08
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CVS Health Corp. (CVS) | $131.18B | 14.08 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $126.01B | 25.80 |
| Stryker Corporation (SYK)vs › | $125.40B | 21.82 |
| Pfizer Inc. (PFE)vs › | $138.21B | 8.14 |
| Danaher Corporation (DHR)vs › | $138.71B | 22.58 |
| Bristol-Myers Squibb Company (BMY)vs › | $118.32B | 9.11 |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.76B | 39.74 |
| Medtronic plc (MDT)vs › | $105.46B | 14.86 |
| GSK plc (GSK)vs › | $105.09B | 14.68 |
| Abbott Laboratories (ABT)vs › | $164.43B | 17.39 |
Trailing vs Forward
Trailing P/E
46.0
reported TTM EPS
Forward P/E
14.1
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $7.42 implies +226.9% EPS growth vs the reported trailing $2.27.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $102.81 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $7.42 | $7.33 – $7.63 | 16 | 13.9x |
| 2027-12-31 | $8.39 | $8.22 – $8.55 | 17 | 12.3x |
| 2028-12-31 | $9.65 | $9.03 – $10.13 | 11 | 10.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for CVS Health Corp. (CVS)?
- The forward PE ratio for CVS stock is 14.08.
Related Metrics
About CVS Health Corp.
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- CEO
- J. David Joyner